Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The authors performed a systematic review to summarize the epidemiologic evidence on the association between use of nonsteroidal antiinflammatory drugs (NSAIDs) and the risk of dementia. A total of 25 case-control and cohort studies that reported an odds ratio/relative risk were included. Study-specific log relative risks were weighted by the inverse of their variances to obtain pooled relative risks and 95% confidence intervals. The authors divided the reports into studies with prevalent dementia cases, studies with incident dementia cases, and studies where cognitive decline was used as the clinical endpoint. The pooled relative risks of the three groups of studies were 0.51 (95% confidence interval (CI): 0.37, 0.70), 0.79 (95% CI: 0.68, 0.92), and 1.23 (95% CI: 0.70, 2.31), respectively. Within these subgroups, heterogeneity was present only in the studies with prevalent cases (p = 0.001). Because the benefit of NSAIDs in preventing dementia or cognitive impairment was 50% in studies with prevalent dementia cases, declined to 20% in studies with incident dementia cases, and was absent in studies where cognitive decline was used as the endpoint, the authors conclude that most of the reported beneficial effects of NSAIDs may result from various forms of bias: recall bias, prescription bias, and publication bias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“Third, it has recently been demonstrated that various NSAIDs have differential propensities on the inflammatory response and deposition of β-amyloid (46).”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 2×
“(35), and the MEDLINE search yielded 337 publications.”
BackgroundMethod(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 4×
“, 2002 (25) Alzheimer’s disease 194 45/1,269 107/1,969 0.”
BackgroundInfluentialNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132 · cited 3×
“, 1997 (20) Alzheimer’s disease 81 Not retrievable/766 Not retrievable/920 0.”
BackgroundNonsteroidal anti-inflammatory drugs in Alzheimer's disease
Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., & Brandt, J. (1995) · Neurology · doi:10.1212/wnl.45.1.51 · Cited by 446 · cited 1×
“Four studies (1–4) were excluded because a relative risk could not be extracted from the report (one study did not report on the association (1), two studies found no association (2, 3), and one study compared the cognitive function of patients who had Alzheimer’s disease and were taking NSAIDs with that of patients w…”
BackgroundBeard, C. M., Waring, S. C., O'Brien, P. C., Kurland, L. T., & Kokmen, E. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.10.951 · Cited by 114
Nilsson, S. E., Johansson, B., Takkinen, S., Zarit, S., McClearn, G., Melander, A., & Berg, S. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0618-y · Cited by 104 · cited 3×
“, 2003 (16) Dementia 179 21/112 158/590 0.”
BackgroundAisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Cited by
Smoking as a Risk Factor for Dementia and Cognitive Decline: A Meta-Analysis of Prospective Studies
Anstey, K. J., von Sanden, C., Salim, A., & O'Kearney, R. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm116 · Cited by 921
Dementia and Cognitive Impairment
Hugo, J., & Ganguli, M. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.001 · Cited by 902
Anstey, K. J., Cherbuin, N., Budge, M., & Young, J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00825.x · Cited by 855
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
“Further clinical investigations with relatively high doses of traditional NSAIDs might be warranted, lthough significant side effects should be anticipated.”
Background
Metadata
- Authors
- de Craen, A. J. M.
- Venue
- American Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-15
- Volume
- 161
- Issue
- 2
- Pages
- 114-120
- ISSN
- 0002-9262 (ISSN-L)
- OpenAlex
- W2099873147
- Cited by
- 123
- References
- 10
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia. https://app.cochat.ai/papers/10.1093/aje/kwi029
- The paper
- de Craen, A. J. M. (2005). Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwi029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.